Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%

• Үндсэн зохиолчид: Qiao Liu (Зохиогч), Zhen Zhou (Зохиогч), Xia Luo (Зохиогч), Lidan Yi (Зохиогч), Liubao Peng (Зохиогч), Xiaomin Wan (Зохиогч), Chongqing Tan (Зохиогч), Xiaohui Zeng (Зохиогч)
• Формат: Ном
• Хэвлэсэн: Frontiers Media S.A., 2022-01-01T00:00:00Z.
• Нөхцлүүд: article
• Онлайн хандалт: Connect to this object online.

Objective To compare the cost-effectiveness of the combination of pembrolizumab and chemotherapy (Pembro+Chemo) versus pembrolizumab monotherapy (Pembro) as the first-line treatment for metastatic non-squamous and squamous non-small-cell lung cancer (NSCLC) with PD-L1expression ≥50%, respectively, f...